Payment overview · 2025
General Payments
$162.93
8 reported records · 4 companies
Healthcare provider profile · identity verified
Lauren Mcgraw, DO
Allopathic & Osteopathic Physicians|Family Medicine · FRUITPORT, MI · NPI 1124558168
Verified facts
What the public records show
CMS Open Payments records show Lauren Mcgraw, DO received $162.93 in general payments during 2025 across 8 reported records.
Novo Nordisk Inc accounted for 40.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Farxiga by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $65.36 | 40.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $48.63 | 29.9% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.48 | 18.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.46 | 11.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $162.93 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $48.63 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $48.63 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.99 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.46 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $16.01 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.47 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 61 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
61 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
70 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 440 | 126 |
| Levothyroxine Sodium | Levothyroxine Sodium | 334 | 85 |
| Lisinopril | Lisinopril | 311 | 83 |
| Amlodipine Besylate | Amlodipine Besylate | 259 | 77 |
| Losartan Potassium | Losartan Potassium | 219 | 62 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 207 | 67 |
| Omeprazole | Omeprazole | 191 | 57 |
| Simvastatin | Simvastatin | 147 | 40 |
| Metformin Hcl Er | Metformin Hcl | 117 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 116 | 35 |
| Alprazolam | Alprazolam | 114 | 34 |
| Trazodone Hcl | Trazodone Hcl | 113 | 25 |
| Meloxicam | Meloxicam | 110 | 29 |
| Gabapentin | Gabapentin | 91 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 90 | 22 |
| Escitalopram Oxalate | Escitalopram Oxalate | 89 | 23 |
| Bupropion Xl | Bupropion Hcl | 81 | 20 |
| Metformin Hcl | Metformin Hcl | 79 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 76 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 23 |
| Carvedilol | Carvedilol | 73 | 23 |
| Montelukast Sodium | Montelukast Sodium | 72 | 18 |
| Eliquis | Apixaban | 70 | 16 |
| Hydrochlorothiazide | Hydrochlorothiazide | 69 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 68 | 15 |
| Allopurinol | Allopurinol | 67 | 17 |
| Potassium Chloride | Potassium Chloride | 63 | 18 |
| Lorazepam | Lorazepam | 61 | 12 |
| Ozempic | Semaglutide | 61 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 61 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 60 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 59 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 58 | 18 |
| Furosemide | Furosemide | 56 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 51 | 18 |
| Estradiol | Estradiol | 45 | 21 |
| Tramadol Hcl | Tramadol Hcl | 45 | 14 |
| Trulicity | Dulaglutide | 45 | suppressed |
| Celecoxib | Celecoxib | 44 | 13 |
| Atenolol | Atenolol | 43 | 11 |
| Cephalexin | Cephalexin | 43 | 21 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 41 | suppressed |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Prednisone | Prednisone | 41 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 37 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | 15 |
| Irbesartan | Irbesartan | 31 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | 11 |
| Finasteride | Finasteride | 29 | suppressed |
| Jardiance | Empagliflozin | 29 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 28 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 28 | 15 |
| Metoprolol Tartrate | Metoprolol Tartrate | 27 | suppressed |
| Xarelto | Rivaroxaban | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Famotidine | Famotidine | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | 11 |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | 14 |
| Valsartan | Valsartan | 17 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Fluconazole | Fluconazole | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 11 |
| Azithromycin | Azithromycin | 14 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 14 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 14 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Methylprednisolone | Methylprednisolone | 11 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Trospium Chloride Er | Trospium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $162.93 · 8 records | Novo Nordisk Inc | BREZTRI, FARXIGA, NURTEC ODT, Ozempic, QULIPTA, UBRELVY, Wegovy, ZAVZPRET | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error